A randomized controlled trial of cognitive remediation and d-cycloserine for individuals with bipolar disorder.

ABSTRACT:

Background

Cognitive remediation (CR) has shown significant promise in addressing the cognitive deficits that accompany serious mental illness. However, this intervention does not appear to completely ameliorate the cognitive deficits that accompany these illnesses. D-cycloserine (DCS), an NMDA receptor partial agonist, has been shown to enhance the therapeutic benefits of learning-based psychosocial interventions for psychiatric disorders. Thus, the goal of this study is to examine the utility of combining cognitive remediation and d-cycloserine in the treatment of cognitive deficits among individuals with bipolar disorder.

Methods/design

Approximately forty individuals with bipolar disorder will be recruited to participate in this study. Participants will be randomized to

SUBMITTER: Breitborde NJ 

PROVIDER: S-EPMC4270034 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature